News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Fuso Pharmaceutical Industries Breaks Up Development Of Cytosine Deaminase Gene Expression Adenovirus Vector


10/19/2005 5:09:37 PM

Fuso Pharmaceutical (TSE: 4538) has conducted research of the vector for gene therapy of cancer with GenVec. However, due to the fact that this research has become out of date, a decision was made to stop the development. The company intends to concentrate efforts on creating safer and more specialized vectors for the cancer cell.

Read at JCN Newswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES